Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15747660 | 0.81 | — | — | |
| SCHEMBL2054828 | 0.79 | — | — | |
| SCHEMBL12495984 | 0.77 | PDE10A (0.35) | — | |
| SCHEMBL4087492 | 0.74 | ALDH1A1 (0.35) | — | |
| SCHEMBL19401 | 0.73 | CA1 (0.34) | — | |
| SCHEMBL10905067 | 0.73 | CA1 (0.34) | — | |
| SCHEMBL14543886 | 0.73 | CA12 (0.31) | — | |
| SCHEMBL12495475 | 0.72 | — | — | |
| SCHEMBL16229341 | 0.72 | — | — | |
| SCHEMBL12495793 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1156449-C | Process for preparing N-(amino-4,6-dihalopyrimidine) formamide | ��¡���ӹɷ�����˾ | 2004-07-07 | — | — | CN | disclosed |
| US-6716981-B2 | BY REACTION OF A 2,5-DIAMINO-4,6-DIHALOPYRIMIDINE WITH FORMIC ACID | LONZA AG (CH) | 2004-04-06 | — | — | US | disclosed |
| EP-1013647-B1 | Process for the preparation of N-(amino-4,6-dihalogenopyrimidin)-formamides | LONZA AG (CH) | 2002-11-27 | — | — | EP | disclosed |
| EP-1188750-A1 | Process for the preparation of 2,5-diamino-4,6-dihalogenopyrimidinen | Lonza AG (CH) | 2002-03-20 | — | — | EP | disclosed |
| US-20010031868-A1 | Process for the preparation of N-(amino-4, 6-dihalo-pyrimidine) formamides | SAIKALI ELIE (CH) | 2001-10-18 | — | — | US | disclosed |
| US-6271376-B1 | Process for the preparation of N-(amino-4,6-dihalo-pyrimidine) formamides | LONZA AG (CH) | 2001-08-07 | — | — | US | disclosed |
| CN-1265393-A | Process for preparing N-(amino-4,6-dihalopyrimidine) formamide | LONZE AG (CH) | 2000-09-06 | — | — | CN | disclosed |
| EP-1013647-A2 | Process for the preparation of N-(amino-4,6-dihalogenopyrimidin)-formamides | Lonza AG (CH) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031868-A1 | Process for the preparation of N-(amino-4, 6-dihalo-pyrimidine) formamides | DPYD, UMPS, DDX41 | MEN1 2205/4885HTT 2595/4885KMT2A 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.